Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 27INDUSTRY 3NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Colonic Neoplasms 32Rectal Neoplasms 31Colorectal Neoplasms 27Unspecified Adult Solid Tumor, Protocol Specific 15Stomach Neoplasms 10Neoplasm Metastasis 7Lung Neoplasms 6Neuroblastoma 5Small Cell Lung Carcinoma 4Pancreatic Neoplasms 4Medulloblastoma 4Lymphoma, Large B-Cell, Diffuse 4Burkitt Lymphoma 4Unspecified Childhood Solid Tumor, Protocol Specific 3Sezary Syndrome 3Sarcoma 3Rhabdomyosarcoma 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neuroectodermal Tumors, Primitive, Peripheral 3Mycosis Fungoides 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Follicular 3Lymphoma, B-Cell, Marginal Zone 3Liver Neoplasms 3Leukemia, Lymphocytic, Chronic, B-Cell 3

Interventions

Magnetic Resonance Spectroscopy 15Specimen Handling 11X-Rays 8Biopsy 8Temozolomide 7Phantoms, Imaging 7Radiotherapy 6Nuclear Medicine Department, Hospital 6Bevacizumab 6erdafitinib 4Surgical Procedures, Operative 4Radiation 4Nivolumab 4Carmustine 4Carboplatin 4ulixertinib 3temsirolimus 3palbociclib 3olaparib 3larotrectinib 3Vorinostat 3Sunitinib 3IL13-PE38 3Chemotherapy, Adjuvant 32,2-dimethyl-N-(6-oxo-6,7-dihydro-5H-dibenzo(b,d)azepin-7-yl)-N'-(2,2,3,3,3-pentafluoropropyl)malonamide 3vandetanib 2trametinib 2tipifarnib 2tazemetostat 2selpercatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Glioma × Irinotecan × Clear all
NCT00393094 2012-07-13

Bevacizumab and Irinotecan to Treat Brain Tumors

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
31 enrolled 12 charts
CNS

Brain Neoplasms, Glioma, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡